Coagulation Cascade

Slide 1 · Coagulation Cascade

How enzymatic amplification produces a fibrin-stabilized hemostatic plug

Tissue factor → thrombin → cross-linked fibrin

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Explain how plasma zymogens, cofactors, and membrane surfaces generate thrombin.

Differentiate laboratory intrinsic/extrinsic pathways from coagulation in vivo.

Relate thrombin, endothelial anticoagulants, and fibrinolysis to clot localization.

Interpret the logic of PT/PTT and selected factor-deficiency phenotypes.

Slide 3 · Hemostasis proceeds from injury to stable clot

Vascular injury

Platelet adhesion and activation

Local coagulation

Cross-linked fibrin

Platelets make the provisional plug; Fibrin stabilizes it.

Slide 4 · Primary and secondary hemostasis

Platelet-centered response

Adhesion to exposed subendothelial matrix

Activation and aggregation

Forms an initial plug

Coagulation-centered response

Sequential protease activation

Thrombin generation

Fibrin formation and cross-linking

The pathways cooperate at the same wound; They are not isolated events.

Slide 5 · What is the coagulation cascade?

Definition

A sequence of amplifying enzymatic reactions.

Most participating factors circulate as inactive plasma proteins.

Proteolytic activation ultimately yields insoluble fibrin.

Local injury exposes the normally hidden initiator, tissue factor.

Slide 6 · Zymogens versus tissue factor

Circulating zymogens

Usually inactive before injury

Become proteolytically active

Represent most clotting factors

Tissue factor (TF)

Cell-associated initiator

Already expressed within vessel wall tissues

Exposed to blood after injury

Coagulation begins when a tissue-localized trigger meets circulating factors.

Slide 7 · Reading coagulation-factor notation

Roman numerals identify clotting factors (II, VII, IX, X).

An appended “a” denotes an activated factor (Xa, IXa, IIa).

Factor II = prothrombin; Factor IIa = thrombin.

Cofactors such as VIIIa and Va accelerate reactions rather than acting as the principal proteases.

Slide 8 · An enzyme–substrate–cofactor reaction

ENZYME

SUBSTRATE

PRODUCT

IXa

X

Xa

Required accelerator/support: VIIIa

Assembly on an appropriate phospholipid membrane is critical.

Slide 9 · Amplification is built into the cascade

Limited initiation

Protease activation

Cofactor activation

Rapid thrombin output

The final fibrin response exceeds the initial triggering signal.

Slide 10 · Two views of coagulation

Laboratory model

Intrinsic and extrinsic entry routes

Defined reagent-triggered reactions

Useful for PT and PTT interpretation

Physiologic model

Tissue factor is the major initiator

TF–VIIa and IXa–VIIIa are central

Thrombin provides positive feedback

The assay diagram is not a literal map of clotting within a vessel.

Slide 11 · The laboratory extrinsic pathway

Tissue factor reagent

Factor VII activation

Factor X → Xa

Thrombin → fibrin

Measured through the prothrombin time (PT).

Slide 12 · The laboratory intrinsic pathway

Contact activator

Factor XII → XIIa

XI → IX → VIII-assisted X activation

Thrombin → fibrin

Measured through the partial thromboplastin time (PTT).

Slide 13 · The shared laboratory pathway

Activated factor X (Xa)

Prothrombin → thrombin

Fibrinogen → fibrin

Clot formation

PT and PTT share the downstream conversion to fibrin.

Slide 14 · PT tests the extrinsic and common pathways

Assesses factors VII, X, V, II (prothrombin), and fibrinogen.

Plasma receives tissue factor, phospholipids, and calcium.

Clot-formation time reflects function of the assayed factor system.

PT is a laboratory assessment—not a direct recording of coagulation in vivo.

Slide 15 · PT assay: Sequence of events

Patient plasma

Add tissue factor + phospholipids + Ca²⁺

Initiate fibrin formation

Measure time to clot

The initiating reagent defines the assay pathway.

Slide 16 · PTT tests the intrinsic and common pathways

Assesses XII, XI, IX, VIII, X, V, II, and fibrinogen.

Negatively charged particles activate contact-dependent clotting.

Phospholipids and calcium support downstream reactions.

The measured endpoint is formation of a fibrin clot.

Slide 17 · PTT assay: Sequence of events

Patient plasma

Add contact activator + phospholipids + Ca²⁺

Initiate factor XII–dependent pathway

Measure time to clot

Contact activation in vitro should not be mistaken for physiologic initiation.

Slide 18 · PT and PTT: Pathway coverage

Assay

Initiating trigger

Factors assessed

PT

Tissue factor

VII, X, V, II, fibrinogen

PTT

Negatively charged surface

XII, XI, IX, VIII, X, V, II, fibrinogen

Both assays test functional ability to reach fibrin formation.

Slide 19 · Why PT/PTT do not recreate hemostasis in vivo

Reagents impose distinct activation routes absent from ordinary vascular injury.

Physiologic clotting is localized to injury-associated cell membranes.

Tissue factor initiates most in-vivo coagulation.

Clinical factor deficiencies expose limitations of the simplified pathway diagram.

Slide 20 · Factor deficiencies challenge the assay model

Greater bleeding impact

Deficiencies of V, VII, VIII, IX, or X

Moderate-to-severe bleeding can occur

Supports key physiologic roles

Factor XI deficiency

Often a milder bleeding phenotype

Thrombin can activate XI by feedback

XI may have additional roles in thrombosis

Laboratory pathway placement alone does not predict bleeding severity.

Slide 21 · Physiologic initiation starts at tissue injury

Vessel wall injury

Tissue factor exposed to blood

TF–VIIa catalytic complex

Activation of IX and X

The major physiologic entry point differs from contact activation.

Slide 22 · Tissue factor and factor VIIa initiate clotting

ENZYME

SUBSTRATE

PRODUCT

Factor VIIa

Factor IX

IXa

Required accelerator/support: Tissue factor (TF)

The TF–VIIa complex is especially important for producing IXa in vivo.

Slide 23 · TF–VIIa has two downstream routes

Direct route

TF–VIIa activates X → Xa

Generates an initiating thrombin signal

Does not eliminate need for amplification

Indirect route

TF–VIIa activates IX → IXa

IXa works with VIIIa

Prominent route to X activation in vivo

Both paths originate from the tissue factor–VIIa complex.

Slide 24 · Factor IX feeds the propagation system

TF–VIIa activates IX

IX → IXa

IXa assembles with VIIIa

X → Xa

IXa–VIIIa is a major physiologic activator of factor X.

Slide 25 · Intrinsic tenase activates factor X

ENZYME

SUBSTRATE

PRODUCT

Factor IXa

Factor X

Factor Xa

Required accelerator/support: Factor VIIIa

“Tenase” denotes an X-activating enzyme system; The complex resides on a phospholipid surface.

Slide 26 · Activated platelet membranes provide a platform

Activated platelets expose negatively charged phospholipid surfaces.

Clotting proteins assemble into membrane-associated reaction complexes.

The same injury that activates platelets also concentrates coagulation.

Spatial organization enhances local conversion of substrates.

Slide 27 · Calcium stabilizes membrane-associated reactions

ENZYME

SUBSTRATE

PRODUCT

Factor IXa

Factor X

Factor Xa

Required accelerator/support: Factor VIIIa + Ca²⁺

Calcium ions help hold the enzyme, substrate, and cofactor together on the phospholipid membrane.

Slide 28 · From factor Xa to thrombin

X → Xa

Xa pairs with Va

II (prothrombin) is cleaved

IIa (thrombin) emerges

The Xa–Va reaction complex links upstream activation to the central effector.

Slide 29 · The prothrombinase reaction

ENZYME

SUBSTRATE

PRODUCT

Factor Xa

Factor II (prothrombin)

Factor IIa (thrombin)

Required accelerator/support: Factor Va

Factor Va accelerates thrombin generation on the membrane surface.

Slide 30 · Tenase and prothrombinase

Tenase complex

Protease IXa

Cofactor VIIIa

Substrate X → product Xa

Prothrombinase complex

Protease Xa

Cofactor Va

Substrate II → product IIa

Both use membrane association and calcium to organize enzymatic activation.

Slide 31 · The central propagation sequence

TF–VIIa

IXa + VIIIa

Xa + Va

Thrombin

Fibrin

A simplified physiologic sequence; TF–VIIa can also activate factor X directly.

Slide 32 · Why thrombin is the central effector

Thrombin (IIa) converts fibrinogen into fibrin.

It reinforces its own production by activating several factors.

It strongly activates platelets through PAR-1.

It signals to endothelial and inflammatory cells.

Slide 33 · Thrombin converts fibrinogen to fibrin

Soluble fibrinogen

Thrombin cleavage

Fibrin monomers

Insoluble fibrin polymer

Fibrin deposition provides the scaffold for secondary hemostasis.

Slide 34 · Fibrin assembly and fibrin stabilization

Polymer formation

Thrombin releases fibrin monomers

Monomers assemble into fibrils

Produces an insoluble fibrin network

Covalent cross-linking

Thrombin activates factor XIII

Factor XIIIa cross-links fibrin

Stabilizes the final hemostatic plug

Polymerization and XIII-mediated cross-linking are distinct steps.

Slide 35 · Factor XIII strengthens the clot

Thrombin activates XIII

XIII → XIIIa

Fibrin strands are cross-linked

Mechanical stability increases

Final clot stabilization depends on more than thrombin-mediated fibrin release.

Slide 36 · Thrombin activates its own cofactors

Early thrombin

Activates both V and VIII

Va and VIIIa enhance complexes

More factor Xa and thrombin

This positive feedback is a major amplification mechanism.

Slide 37 · Thrombin can activate factor XI

Thrombin formed

Factor XI → XIa

Additional IX activation

Sustained propagation

Feedback activation helps explain how XI participates despite limited in-vivo initiation.

Slide 38 · Initiation and amplification answer different questions

Initiation

Where does clotting begin?

Tissue factor is exposed at injury

TF–VIIa starts downstream proteolysis

Amplification

How does output become large?

IXa–VIIIa and Xa–Va complexes

Thrombin activates V, VIII, and XI

Separating the two phases makes the cascade easier to interpret.

Slide 39 · Thrombin activates platelets through PAR-1

Thrombin binds and cleaves PAR-1

Platelet activation

Aggregation and degranulation

Enhanced hemostatic plug

PAR-1 links enzymatic coagulation to primary hemostasis.

Slide 40 · Platelets and coagulation reinforce one another

Platelets support coagulation

Provide phospholipid reaction surfaces

Release calcium during activation

Concentrate clot formation at injury

Coagulation supports platelets

Thrombin activates PAR-1

Induces aggregation/degranulation

Fibrin consolidates platelet plug

Primary and secondary hemostasis form an interdependent system.

Slide 41 · Thrombin signals beyond the clot

Protease-activated receptors occur on endothelium and inflammatory cells.

Thrombin signaling may promote leukocyte responses.

The source links these effects to tissue repair and angiogenesis.

These cellular effects are distinct from thrombin’s direct fibrin-forming activity.

Slide 42 · Thrombin has hemostatic and cellular outputs

Direct clotting functions

Fibrinogen → fibrin

XIII → XIIIa

Activation of V, VIII, and XI

Cell signaling functions

Platelet activation via PAR-1

Endothelial responses

Inflammatory-cell activation

One protease integrates hemostasis and injury responses.

Slide 43 · Thrombin can switch to anticoagulant signaling

On intact endothelium, thrombin can bind thrombomodulin.

The thrombin–thrombomodulin system activates protein C.

This suppresses factors Va and VIIIa with protein S as cofactor.

The switch restricts extension beyond injured tissue.

Slide 44 · How a clot stays confined to injury

Tissue factor exposure is concentrated at the wounded vessel wall.

Activated platelet membranes localize major enzyme complexes.

Neighboring intact endothelium presents anticoagulant safeguards.

Fibrinolysis limits clot size and supports later dissolution.

Slide 45 · Blood flow reduces activated-factor persistence

Flowing blood dilutes and washes activated proteins from injury sites.

The liver removes circulating activated coagulation factors.

These processes complement endothelial anticoagulant mechanisms.

Flow-based removal alone is not the entire control system.

Slide 46 · Membrane dependence is a spatial safeguard

Several major enzyme complexes require anionic phospholipids.

These surfaces are enriched on platelets activated at vascular injury.

Coagulation becomes markedly more effective at appropriate local surfaces.

This helps confine reactions even while zymogens circulate throughout plasma.

Slide 47 · Intact versus activated endothelium

Intact endothelium

Shields blood from tissue factor

Presents anticoagulant proteins

Supports fibrinolysis

Injured / activated endothelium

Barrier protection is disrupted

Antithrombotic phenotype can diminish

Favors local clot formation

The endothelial state strongly influences clot growth or dissolution.

Slide 48 · Thrombomodulin changes thrombin’s substrate

Thrombin at intact endothelium

Binding to thrombomodulin

Protein C activation

Va and VIIIa inhibition

EPCR binds protein C and assists its activation at the endothelial surface.

Slide 49 · Activated protein C attenuates propagation

ENZYME

SUBSTRATE

PRODUCT

Activated protein C

Factors Va and VIIIa

Reduced cofactor activity

Required accelerator/support: Protein S

Inactivation of cofactors diminishes both tenase and prothrombinase efficiency.

Slide 50 · Protein S cooperates with activated protein C

Protein S functions as a cofactor for activated protein C.

Its best-established pathway here is suppression of Va and VIIIa.

The source also discusses additional candidate anticoagulant actions.

Protein S deficiency may increase propensity to inappropriate clot formation.

Slide 51 · Endothelial heparin-like molecules stimulate antithrombin

Endothelial heparin-like molecules

Antithrombin activity increases

Several active serine proteases inhibited

Reduced extension of coagulation

The heparin class of drugs exploits the same antithrombin-related mechanism.

Slide 52 · Antithrombin targets multiple active factors

Primary inhibitor

Coagulation targets

Effect

Antithrombin

IIa (thrombin)

Limits fibrin production

Antithrombin

IXa and Xa

Restrains propagation

Antithrombin

XIa and XIIa

Restrains upstream serine proteases

Endothelial heparin-like molecules potentiate antithrombin activity.

Slide 53 · Tissue factor pathway inhibitor restrains initiation

TF–VIIa initiation complex

TFPI binds/inhibits pathway

Further TF-dependent activation falls

Propagation becomes restricted

The source identifies protein S as a TFPI cofactor.

Slide 54 · Three endothelial anticoagulant strategies

Mechanism

Key mediator

Principal action

Cofactor inactivation

Thrombomodulin / EPCR / protein C / S

Inhibit Va and VIIIa

Protease inhibition

Heparin-like molecules / antithrombin

Inhibit IIa, IXa, Xa, XIa, XIIa

Initiation inhibition

TFPI

Oppose TF–VIIa complexes

Different brakes operate at different levels of the cascade.

Slide 55 · Coagulation triggers its counter-process

Fibrin clot develops

Plasminogen is recruited

Plasmin is generated

Fibrin is degraded

Fibrinolysis both limits clot size and supports later dissolution.

Slide 56 · T-PA localizes plasmin generation

Endothelium is the main source of tissue plasminogen activator (t-PA).

T-PA acts most effectively when bound to fibrin.

It converts circulating plasminogen to plasmin.

The localization helps focus fibrinolysis at fibrin-rich sites.

Slide 57 · The fibrinolytic protease is plasmin

Plasminogen

T-PA / plasminogen activators

Plasmin

Fibrin breakdown products

Plasmin opposes persistent fibrin and can interfere with fibrin polymerization.

Slide 58 · Fibrinolysis is also regulated

Promote fibrin breakdown

T-PA: Activates plasminogen

Plasmin: Cleaves fibrin

Fibrin binding localizes activity

Restrain excess breakdown

α₂-antiplasmin inhibits free plasmin

PAI opposes plasminogen activators

Prevents indiscriminate proteolysis

Fibrinolysis requires negative regulation as well as activation.

Slide 59 · D-dimer reflects fibrin turnover

Fibrin breakdown produces circulating degradation products.

D-dimer is a fibrin-derived breakdown marker.

The source associates elevated D-dimer with several thrombotic states.

It is not a direct readout of which coagulation initiation pathway was used.

Slide 60 · Normal hemostasis versus pathological thrombosis

Normal local response

Triggered at vascular injury

Confined by endothelial inhibitors

Eventually remodeled by fibrinolysis

Pathologic extension

Inhibition becomes inadequate

Activated factors are insufficiently constrained

Clot can propagate inappropriately

The physiologic cascade must be balanced, not merely switched on.

Slide 61 · A functional map of the cascade

Functional stage

Major factor(s)

Biologic purpose

Initiation

TF–VIIa

Activate IX and X

Amplification

IXa–VIIIa, Xa–Va, thrombin

Increase thrombin output

Clot formation

IIa, fibrinogen

Generate fibrin polymers

Stabilization

XIIIa

Cross-link fibrin

Containment

Protein C/S, antithrombin, TFPI

Restrict excessive propagation

This is a functional synthesis, not an additional literal laboratory pathway.

Slide 62 · Clinical reasoning: What does PTT test?

A laboratory activates plasma with a negatively charged reagent and records time to fibrin formation. Which pathway is deliberately initiated?

A. Tissue-factor pathway only

B. Contact/intrinsic pathway

C. Fibrinolysis

D. Platelet adhesion alone

Answer: B. Contact/intrinsic pathway

PTT includes XII, XI, IX, VIII and the common-pathway factors.

Slide 63 · Clinical reasoning: Factor XI deficiency

Why can a factor XI deficiency cause less bleeding than the classical intrinsic pathway diagram might suggest?

A. Factor XI makes fibrin directly

B. In-vivo coagulation is principally TF-initiated

C. Factor XI is identical to tissue factor

D. PTT never involves factor XI

Answer: B. In-vivo coagulation is principally TF-initiated

Thrombin feedback can activate XI; Laboratory pathway placement does not equal physiologic primacy.

Slide 64 · Clinical reasoning: Stabilize the fibrin network

A clot contains fibrin monomers but needs covalent cross-linking. Which factor does thrombin activate to support this step?

A. Factor XII

B. Factor VII

C. Factor XIII

D. Protein S

Answer: C. Factor XIII

Factor XIIIa covalently cross-links fibrin after thrombin has generated fibrin monomers.

Slide 65 · Clinical reasoning: Confining a clot

Which mechanism most directly inactivates the propagation cofactors Va and VIIIa at adjacent intact endothelium?

A. T-PA alone

B. Activated protein C with protein S

C. TF–VIIa

D. Fibrinogen

Answer: B. Activated protein C with protein S

Thrombin–thrombomodulin shifts thrombin activity toward protein C activation.

Slide 66 · Coagulation: Integrated synthesis

TF–VIIa is the major in-vivo initiator, with IXa–VIIIa central to X activation.

Xa–Va generates thrombin; Thrombin produces and stabilizes fibrin.

Platelets, calcium, and phospholipid surfaces organize the cascade locally.

Intact endothelium and fibrinolysis prevent unlimited clot propagation.

Slide 67 · Selected reading

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. (2026). Chapter 4: Hemodynamic Disorders, Thromboembolic Disease, and Shock.

See the source discussion of coagulation, endothelial anticoagulants, and the fibrinolytic system.